Butt, Heba and Hunter, Louise
2025.
Will pharmacotherapy soon replace bariatric surgery as the gold standard treatment for obesity?
The British Student Doctor Journal
8
(1)
10.18573/bsdj.419
|
Preview |
PDF
- Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (2MB) | Preview |
Abstract
Background: Obesity remains a substantial and growing global health issue, contributing significantly to comorbidities such as type 2 diabetes, cardiovascular disease, and reduced quality of life. As the prevalence of obesity continues to rise, clinicians must help people living with obesity to navigate the increasing range of treatment options. Bariatric surgery has been regarded as the gold standard treatment for severe obesity, due to its consistent and substantial weight loss outcomes. However, recent advancements in pharmacotherapies targeting appetite regulation and metabolic pathways, particularly GLP-1 receptor agonists, have prompted renewed interest in medical management as a potentially effective and more accessible alternative. Methods: A narrative review was conducted using PubMed, Cochrane, and NICE guideline databases covering studies from 2000 to 2024. Inclusion criteria encompassed clinical trials, meta-analyses, and national health policy reports. Exclusion criteria included non-English sources and case studies with <10 participants. Search terms included “bariatric surgery”, “GLP-1”, “obesity pharmacotherapy”, and “obesity management UK”. Data were analysed for treatment efficacy, safety, cost-effectiveness, accessibility, and long-term outcomes. Bias risk and funding sources were noted where applicable. Results: Evidence indicates that bariatric surgery achieves greater and more sustained weight loss (up to 70% excess weight loss) and improved long-term comorbidity remission, but carries surgical risks and access barriers. New pharmacotherapies such as semaglutide and tirzepatide achieve 15-25% total body weight loss with favourable safety profiles, however long-term outcomes and accessibility remain concerns. Conclusion: While pharmacotherapy shows promise, especially for less severe obesity or surgery-ineligible patients, it is unlikely to fully replace bariatric surgery in the near future. A combined, patient-centred approach may be the future standard. For clinicians, especially those in training, understanding both approaches is essential for offering tailored treatment strategies based on individual needs and preferences, in order to improve outcomes in obesity management.
| Item Type: | Article |
|---|---|
| Date Type: | Publication |
| Status: | Published |
| Subjects: | R Medicine > R Medicine (General) |
| Publisher: | Cardiff University Press |
| ISSN: | 2514-3174 |
| Date of First Compliant Deposit: | 14 October 2025 |
| Date of Acceptance: | 11 June 2025 |
| Last Modified: | 14 Oct 2025 14:40 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/181659 |
Actions (repository staff only)
 |
Edit Item |
Dimensions
Dimensions